Moleculin Biotech Inc, (Nasdaq: MBRX), a clinical stage pharmaceutical company, has revealed additional preliminary data from the Phase one clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, in patients with glioblastoma, it was reported on Tuesday.
This move supports the progression of the trial to the fourth and final dose escalation cohort. The company has completed treatment of three patients in the third cohort at a dose level of 8mg/kg with no adverse events related to the product and the study will now proceed to the next higher dose of 16mg/kg.
Walter Klemp, Moleculin chairman and CEO, said, 'On the heels of our recent positive announcement regarding the progress of the paediatric brain tumour trial of WP1066, we are pleased to also report on the progress of the adult GBM clinical trial for the same drug candidate. The trial in adults has been important in leading the way to establishing a safe and tolerable human dose level for what we believe is a first-in-class compound that crosses the blood-brain barrier and is being developed for the treatment of central nervous system malignancies. In animal models, WP1066 has been shown to stimulate immune responses that successfully modulate oncogenic transcriptional activity in tumour cells and repress their ability to drive tumour growth.'
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference